Quarterly Activities/Appendix 4C Cash Flow Report
Released
Released
Announcement PDF
RAD
RADIOPHARM THERANOSTICS
Quarterly Activities & Cash Report
and 4C for the quarter ended
30 June 2023
ASX ANNOUNCEMENT
31 JULY 2023
QUARTERLY ACTIVITIES AND CASH FLOW REPORT
QUARTER ENDED 30 JUNE 2023
Highlights:
• Orphan Drug Designation granted by FDA for Ga68-Trivehexin (RAD 301)
• Successful completion of pre-Investigational New Drug (IND) meeting with the FDA
concerning F18-pivalate (RAD 101)
• Supply agreement announced with TerThera for the provision of the isotope
Terbium-161 (Tb-161)
• Educational webinar hosted on Pivalate platform technology
Sydney, Australia – 31 July 2023 – Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the
“Company”), a developer of a world-class platform of radiopharmaceutical products for both
diagnostic and therapeutic uses, is pleased to provide a summary of its activities for the quarter ended
30 June 2023.
RAD 301 receives FDA Orphan Drug Designation
In May, Radiopharm announced that the US Food and Drug Administration (FDA) had granted Orphan
Drug Designation for Ga68-Trivehexin (RAD 301), a radiopharmaceutical technology for imaging
patients with pancreatic ductal adenocarcinoma (PDAC).
Radiopharm is developing Trivehexin as a unique radiopharmaceutical for both imaging and treatment
of pancreatic cancer. Trivehexin, a proprietary peptide-based molecule, targets αvβ6-integrin, a
cellular indicator of tumour invasion and metastatic growth. Its expression correlates with decreased
survival in several carcinomas, and it is found in high density on most pancreatic carcinoma cells,
rendering it a valuable diagnostic and therapeutic target.
The Company currently holds two FDA Orphan Drug Designations, the other being the LRRC15
antibody DUNP19 for treating patients with osteosarcoma. The designation is awarded to a drug or
biologic product that has potential to diagnose, prevent, or treat rare diseases and conditions. Those
granted the designation receive benefits and incentives such as tax credits for qualifying clinical trials,
exemption from user fees, and potential seven-year market exclusivity if the drug is approved.
Radiopharm signed an exclusive licensing agreement with TRIMT GmbH for the development and
commercialisation of RAD 301 in the USA, Australia, China, Hong Kong, and Japan.
FDA Pre-IND meeting supports an IND application for RAD 101
Radiopharm also announced the completion of a successful pre-Investigational New Drug (IND)
meeting with the FDA concerning F18-pivalate (RAD 101), representing a significant milestone towards
the IND application for the Company's late-stage clinical trials.
Following positive guidance from the FDA, Radiopharm will file an IND application to commence a
multi-centre trial for imaging brain metastasis in Q3 2023, with plans to administer the first patient
dose by the end of the year.
Radiopharm Theranostics Limited
Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia
ABN: 57 647 877 889
ASX ANNOUNCEMENT
31 JULY 2023
RAD 101 is a proprietary imaging agent made of F18 radioisotope and pivalate, a small molecule that
targets fatty acid synthetase. October 2022 saw encouraging data from the Imperial College of
London's Phase IIa imaging trial of RAD 101 in patients with brain metastases, showing notable tumour
uptake that was consistent with and independent from the tumour of origin, supporting pivalate's
potential for monitoring cerebral metastasis.
Radiopharm holds an exclusive global license for the pivalate platform technology and maintains a
collaboration with the Imperial College of London to develop a therapeutic candidate that leverages
the same mechanism of action.
Pivalate (RAD-101) brain glioma imaging study published in prestigious peer reviewed journal
In a media release issued subsequent to the end of the quarter, Radiopharm announced that a report
of the first study of F18-Pivalate (RAD 101) PET in patients with glioma was published in the
prestigious, peer reviewed European Journal of Nuclear Medicine and Molecular Imaging.
The original article titled “Feasibility of [18F]fluoropivalate hybrid PET/MRI for imaging lower and
higher grade glioma: a prospective first-in-patient pilot study”1 reported RAD 101 data and suggested
potential for additional indications in Glioblastoma.
Data presented from ten adult glioma subjects showed significant tumor uptake in high grade gliomas,
with safety and tolerability in all patients dosed. The results support further investigation of RAD 101
pivalate for PET/MRI brain tumor imaging in a larger patient population.
Agreement with TerThera to supply Terbium-161 isotope
In June, the Company announced a supply agreement with TerThera for the provision of the isotope
Terbium-161 (Tb-161). This isotope will be combined with a unique peptide to create RAD 602, a
radiotherapeutic agent designed by Radiopharm to target protein tyrosine phosphatase mu (PTPμ), a
protein primarily found in cancer cells. During Q4 2023 Radiopharm will initiate a Phase I trial of RAD
602 for the treatment of brain cancer patients.
Terbium-161 has been identified as a promising isotope for targeted cancer therapy, due to its
radiation characteristics, which include both Auger electrons and short-range beta particles. The
isotope's bioequivalence shows promise for comparable biodistribution to existing radiolanthanides
and potential superiority over Lutetium-177 (Lu-177), due to its enhanced potency and efficacy in
destroying tumour cells while sparing healthy tissue.
The costs of acquiring Tb-161 are not significant to RAD’s annual budget and will be covered from
existing funds. Preclinical use orders were completed in April 2023, and clinical use orders are
expected in October 2023. The supply agreement, effective as of 17 April 2023, spans three years,
with a potential two-year extension, unless otherwise agreed.
Radiopharm will retain all data and discoveries from its clinical trials.
1 https://link.springer.com/article/10.1007/s00259-023-06330-0
Radiopharm Theranostics Limited
Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia
ABN: 57 647 877 889
ASX ANNOUNCEMENT
31 JULY 2023
Financial Update
An Appendix 4C Quarterly Cash Flow Report is attached to this announcement.
As detailed in the attached Appendix 4C, the Company had $11.7 million in cash equivalents as at 30
June 2023, decreasing from $19.3 million at 31 March 2023. This will support the Company’s activities
to progress the clinical trials that are underway.
The net cash used in operating activities during the quarter was $7.7 million with direct Research and
Development expenditure and Staff costs accounting for 87% of the operating expenditure.
In accordance with Listing Rule 4.7C, payments made to related parties and their associates included
in items 6.1 of the Appendix 4C includes sign on payment, payments for directors’ fees and
remuneration in the normal course of business at commercial rates, excluding reimbursements ofout-of pocket expenses.
Pursuant to Listing Rule 4.7C.2, the Company confirms that for the period since listing on the ASX, it
has incurred expenditure largely in line with the Use of Proceeds.
Use of Funds under
Prospectus
Offer Costs - IPO1
License fees1
Admin/corporate and
general working2
Employment2
Sponsored research
agreements2
Milestones1
Phase 1 clinical trials
and manufacturing3
Total
Funds
allocated
under
Prospectus
Funds expected
allocation
between
admission and 30
June 2023
$4,035,282
$12,760,417
$4,035,282
$12,760,417
Funds
expended
between
admission
and 30 June
2023
$3,643,845
$13,249,949
$2,835,962
$2,363,851
$4,752,244
($2,388,393) (101%)
$9,543,591
$7,787,690
$10,284,145
($2,496,455)
(32%)
$3,951,266
$3,960,717
$4,886,800
($926,083)
(23%)
$6,172,980
$0
$0
$0
0%
$10,700,502
$10,700,502
$9,663,943
$1,036,559
10%
$50,000,000
$41,608,459
$46,480,926
($4,872,467)
(12%)
Variance
$391,437
($489,532)
10%
(4%)
1 Costs remain largely In line with expected use of funds.
2 Increased expenditure relating to hiring additional employees and engaging in additional corporate and research
activities.
3 Costs incurred are lower compared to funds allocated under prospectus as a result to lower Manufacturing and Preclinical
spending requirements and the payment scheduling.
Expenditure in the above table relates only to the $50 million raised during the Initial Public Offering
and does not include the expenditure of the funds raised during the Convertible Note raise or the
November 2022 entitlement offer.
Radiopharm Theranostics Limited
Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia
ABN: 57 647 877 889
ASX ANNOUNCEMENT
31 JULY 2023
Educational webinar
During the quarter the Company hosted an educational webinar on its Pivalate platform technology
for shareholders and interested parties.
Radiopharm CEO and Managing Director Riccardo Canevari provided an overview on the encouraging
pre-IND meeting with FDA, Pivalate late-stage development plan and market opportunity.2
About Radiopharm Theranostics
Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class
platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in
areas of high unmet medical need. Radiopharm has been listed on ASX (RAD) since November 2021.
The company has a pipeline of six distinct and highly differentiated platform technologies spanning
peptides, small molecules and monoclonal antibodies for use in cancer, in pre-clinical and clinical
stages of development from some of the world’s leading universities and institutes. The pipeline has
been built based on the potential to be first to market or best in class. The clinical program includes
one Phase II and three Phase I trials in a variety of solid tumour cancers including breast, kidney and
brain. Learn more at RadiopharmTheranostics.com.
Authorised on behalf of the Radiopharm Theranostics board of directors by Executive Chairman Paul
Hopper.
For more information:
Riccardo Canevari
CEO & Managing Director
P: +1 862 309 0293
E: rc@radiopharmtheranostics.com
Paul Hopper
Executive Chairman
P: +61 406 671 515
E: paulhopper@lifescienceportfolio.com
Timothy McCarthy
Investor Relations
LifeSci Advisors, LLC
P: +1 917 679 9282
E: tim@lifesciadvisors.com
Matt Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au
Follow Radiopharm Theranostics:
Website – https://radiopharmtheranostics.com/
Twitter – https://twitter.com/TeamRadiopharm
Linked In – https://www.linkedin.com/company/radiopharm-theranostics/
2 The replay can be viewed at: https://youtu.be/e0J7aphfyig
Radiopharm Theranostics Limited
Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia
ABN: 57 647 877 889
Rule 4.7B
Appendix 4C
Quarterly cash flow report for entities
subject to Listing Rule 4.7B
Name of entity
Radiopharm Theranostics Limited
ABN
Quarter ended (“current quarter”)
57 647 877 889
30 June 2023
Consolidated statement of cash flows
Current quarter
$A’000
1.
Cash flows from operating activities
1.1
Receipts from customers
1.2
Payments for
Year to date
(12 months)
$A’000
-
292
(4,585)
(13,371)
-
-
(114)
(575)
-
-
(e) staff costs
(2,062)
(7,858)
(f)
(1,021)
(3,787)
-
-
36
144
(a) research and development
(b) product manufacturing and operating
costs
(c) advertising and marketing
(d) leased assets
administration and corporate costs
1.3
Dividends received (see note 3)
1.4
Interest received
1.5
Interest and other costs of finance paid
-
-
1.6
Income taxes paid
-
-
1.7
Government grants and tax incentives
-
1,555
1.8
Other – GST refunded
91
397
1.9
Net cash from / (used in) operating
activities
(7,655)
(23,203)
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 1
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
Consolidated statement of cash flows
2.
Cash flows from investing activities
2.1
Payments to acquire or for:
2.2
Current quarter
$A’000
Year to date
(12 months)
$A’000
(a) entities
-
-
(b) businesses
-
-
(c) property, plant and equipment
-
(45)
(d) investments
-
(1,485)
(e) intellectual property
-
-
(f)
-
-
(a) entities
-
-
(b) businesses
-
-
(c) property, plant and equipment
-
-
(d) investments
-
-
(e) intellectual property
-
-
(f)
-
-
other non-current assets
Proceeds from disposal of:
other non-current assets
2.3
Cash flows from loans to other entities
-
-
2.4
Dividends received (see note 3)
-
-
2.5
Other (provide details if material)
-
-
2.6
Net cash from / (used in) investing
activities
-
(1,530)
3.
Cash flows from financing activities
3.1
Proceeds from issues of equity securities
(excluding convertible debt securities)
-
10,073
3.2
Proceeds from issue of convertible debt
securities
-
-
3.3
Proceeds from exercise of options
-
-
3.4
Transaction costs related to issues of
equity securities or convertible debt
securities
-
(855)
3.5
Proceeds from borrowings
-
-
3.6
Repayment of borrowings
-
-
3.7
Transaction costs related to loans and
borrowings
-
-
3.8
Dividends paid
-
-
3.9
Other
-
-
3.10
Net cash from / (used in) financing
activities
-
9,218
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 2
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
Consolidated statement of cash flows
4.
Net increase / (decrease) in cash and
cash equivalents for the period
4.1
Cash and cash equivalents at beginning of
period
4.2
Net cash from / (used in) operating
activities (item 1.9 above)
4.3
Current quarter
$A’000
Year to date
(12 months)
$A’000
19,268
26,979
(7,655)
(23,203)
Net cash from / (used in) investing activities
(item 2.6 above)
-
(1,530)
4.4
Net cash from / (used in) financing activities
(item 3.10 above)
-
9,218
4.5
Effect of movement in exchange rates on
cash held
86
235
4.6
Cash and cash equivalents at end of
period
11,699
11,699
5.
Reconciliation of cash and cash
equivalents
Current quarter
$A’000
Previous quarter
$A’000
at the end of the quarter (as shown in the
consolidated statement of cash flows) to the
related items in the accounts
5.1
Bank balances
11,699
19,268
5.2
Call deposits
5.3
Bank overdrafts
-
-
5.4
Other (provide details)
-
-
5.5
Cash and cash equivalents at end of
quarter (should equal item 4.6 above)
11,699
19,268
6.
Payments to related parties of the entity and their
associates
6.1
Aggregate amount of payments to related parties and their
associates included in item 1
452
6.2
Aggregate amount of payments to related parties and their
associates included in item 2
-
-
Current quarter
$A'000
Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an
explanation for, such payments.
In accordance with Listing Rule 4.7C, payments made to related parties and their associates included
in items 6.1 of the Appendix 4C includes compensation and director fee related payments in the normal
course of business at commercial rates, excluding reimbursements of out-of-pocket expenses.
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 3
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
7.
Financing facilities
Note: the term “facility’ includes all forms of financing
arrangements available to the entity.
Add notes as necessary for an understanding of the
sources of finance available to the entity.
Total facility
amount at quarter
end
$A’000
Amount drawn at
quarter end
$A’000
7.1
Loan facilities
-
-
7.2
Credit standby arrangements
-
-
7.3
Other (please specify)
-
-
7.4
Total financing facilities
-
-
7.5
Unused financing facilities available at quarter end
7.6
Include in the box below a description of each facility above, including the lender, interest
rate, maturity date and whether it is secured or unsecured. If any additional financing
facilities have been entered into or are proposed to be entered into after quarter end,
include a note providing details of those facilities as well.
-
N/A
8.
Estimated cash available for future operating activities
$A’000
8.1
Net cash from / (used in) operating activities (item 1.9)
(7,655)
8.2
Cash and cash equivalents at quarter end (item 4.6)
11,699
8.3
Unused finance facilities available at quarter end (item 7.5)
8.4
Total available funding (item 8.2 + item 8.3)
8.5
Estimated quarters of funding available (item 8.4 divided by
item 8.1)
11,699
1.5
Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as “N/A”. Otherwise, a
figure for the estimated quarters of funding available must be included in item 8.5.
8.6
If item 8.5 is less than 2 quarters, please provide answers to the following questions:
8.6.1
Does the entity expect that it will continue to have the current level of net operating
cash flows for the time being and, if not, why not?
Answer: The Company anticipates maintaining a similar level of net operating cash flows for
the time being and management continue to evaluate the use of funds based on
available capacity and priorities.
8.6.2
Has the entity taken any steps, or does it propose to take any steps, to raise further
cash to fund its operations and, if so, what are those steps and how likely does it
believe that they will be successful?
Answer: The Board believe that the Company can raise sufficient capital on the basis of
past success and current interest in the company and its projects. The Board
continues to evaluate alternative sources of capital.
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 4
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
8.6.3
Does the entity expect to be able to continue its operations and to meet its business
objectives and, if so, on what basis?
Answer: Yes, the Board expects to be able to continue its operations and to meet its
business objectives. The Board believe that the Company can raise sufficient
capital on the basis of past success and current interest in the company and its
projects. The Board continues to evaluate alternative sources of capital.
Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.
Compliance statement
1
This statement has been prepared in accordance with accounting standards and policies
which comply with Listing Rule 19.11A.
2
This statement gives a true and fair view of the matters disclosed.
Date:
31 July 2023
Authorised by: The Board
(Name of body or officer authorising release – see note 4)
Notes
1.
This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the
entity’s activities for the past quarter, how they have been financed and the effect this has had on its cash position. An
entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is
encouraged to do so.
2.
If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions
in, and provisions of, AASB 107: Statement of Cash Flows apply to this report. If this quarterly cash flow report has been
prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the
corresponding equivalent standard applies to this report.
3.
Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities,
depending on the accounting policy of the entity.
4.
If this report has been authorised for release to the market by your board of directors, you can insert here: “By the board”.
If it has been authorised for release to the market by a committee of your board of directors, you can insert here: “By the
[name of board committee – eg Audit and Risk Committee]”. If it has been authorised for release to the market by a
disclosure committee, you can insert here: “By the Disclosure Committee”.
5.
If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as
complying with recommendation 4.2 of the ASX Corporate Governance Council’s Corporate Governance Principles and
Recommendations, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial
records of the entity have been properly maintained, that this report complies with the appropriate accounting standards
and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a
sound system of risk management and internal control which is operating effectively.
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 5
Quarterly Activities & Cash Report
and 4C for the quarter ended
30 June 2023
ASX:RAD
RAD
RADIOPHARM THERANOSTICS
Share your feedback
Discover